In the National Academy of Sciences in the United states of America 106: 48344839. 13. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, et al. Stathmin and tubulin expression and survival of ovarian cancer patients getting platinum remedy with and without paclitaxel. Cancer 115: 24532463. 14. Trovik J, Mauland KK, Werner HM, Wik E, Helland H, et al. Enhanced survival connected to adjustments in endometrial cancer treatment, a 30-year population based viewpoint. Gynecol Oncol 125: 381387. 15. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, et al. Stathmin overexpression identifies high-risk individuals and lymph node metastasis in endometrial cancer. Clin Cancer Res 17: 33683377. 16. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, et al. Poor prognosis in carcinoma is related to a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings from the National Academy of Sciences on the United states of america of America 104: 75647569. 17. Salvesen HB, Haldorsen IS, Trovik J Markers for individualised therapy in endometrial carcinoma. The lancet oncology 13: e353361. 18. La Thangue NB, Kerr DJ Predictive biomarkers: a paradigm shift towards Autophagy customized cancer medicine. Nature evaluations Clinical oncology eight: 587 596. 19. Sawyers C Targeted cancer therapy. Nature 432: 294297. 20. Ong FS, Das K, Wang J, Vakil H, Kuo JZ, et al. Customized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Specialist review of molecular diagnostics 12: 593602. 21. Shankaran V, Obel J, Benson AB 3rd Predicting response to EGFR inhibitors in metastatic colorectal cancer: present inhibitor practice and future directions. The oncologist 15: 157167. 22. Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. The New England journal of medicine 363: 17271733. 23. Hudis CA Trastuzumab mechanism of action and use in clinical practice. The New England journal of medicine 357: 3951. 24. Alli E, Bash-Babula J, Yang JM, Hait WN Effect of stathmin around the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 68646869. 25. Alli E, Yang JM, Ford JM, Hait WN Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Molecular pharmacology 71: 12331240. 26. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 50545063. 27. Mistry SJ, Atweh GF Therapeutic interactions involving stathmin inhibition and chemotherapeutic agents in prostate cancer. Molecular cancer therapeutics 5: 32483257. 28. Mitra M, Kandalam M, Sundaram CS, Verma RS, Maheswari UK, et al. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Investigative ophthalmology & visual science 52: 5441 5448. 29. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 1846921 483: 603607. 30. American Type Culture Collection Standards Development Organization Workgroup ASN Cell line misidentification: the beginning on the end. Nat Rev Cancer 10: 441448. 31. Lacroix M Persistent use of ��false��cell lines. International journal of cancer Journal international du cancer 122: 14. 32. Eisenhauer EA, Therasse P, Bogaerts J, Schwa.With the National Academy of Sciences in the United states of America 106: 48344839. 13. Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, et al. Stathmin and tubulin expression and survival of ovarian cancer individuals receiving platinum therapy with and with out paclitaxel. Cancer 115: 24532463. 14. Trovik J, Mauland KK, Werner HM, Wik E, Helland H, et al. Enhanced survival associated to adjustments in endometrial cancer therapy, a 30-year population primarily based viewpoint. Gynecol Oncol 125: 381387. 15. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, et al. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer. Clin Cancer Res 17: 33683377. 16. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, et al. Poor prognosis in carcinoma is linked to a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings with the National Academy of Sciences on the Usa of America 104: 75647569. 17. Salvesen HB, Haldorsen IS, Trovik J Markers for individualised therapy in endometrial carcinoma. The lancet oncology 13: e353361. 18. La Thangue NB, Kerr DJ Predictive biomarkers: a paradigm shift towards customized cancer medicine. Nature evaluations Clinical oncology eight: 587 596. 19. Sawyers C Targeted cancer therapy. Nature 432: 294297. 20. Ong FS, Das K, Wang J, Vakil H, Kuo JZ, et al. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Specialist overview of molecular diagnostics 12: 593602. 21. Shankaran V, Obel J, Benson AB 3rd Predicting response to EGFR inhibitors in metastatic colorectal cancer: present practice and future directions. The oncologist 15: 157167. 22. Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. The New England journal of medicine 363: 17271733. 23. Hudis CA Trastuzumab mechanism of action and use in clinical practice. The New England journal of medicine 357: 3951. 24. Alli E, Bash-Babula J, Yang JM, Hait WN Effect of stathmin around the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62: 68646869. 25. Alli E, Yang JM, Ford JM, Hait WN Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Molecular pharmacology 71: 12331240. 26. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 50545063. 27. Mistry SJ, Atweh GF Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Molecular cancer therapeutics 5: 32483257. 28. Mitra M, Kandalam M, Sundaram CS, Verma RS, Maheswari UK, et al. Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention. Investigative ophthalmology & visual science 52: 5441 5448. 29. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 1846921 483: 603607. 30. American Type Culture Collection Standards Development Organization Workgroup ASN Cell line misidentification: the beginning on the end. Nat Rev Cancer 10: 441448. 31. Lacroix M Persistent use of ��false��cell lines. International journal of cancer Journal international du cancer 122: 14. 32. Eisenhauer EA, Therasse P, Bogaerts J, Schwa.
